VCs Turn to Late-Stage Devices
This article was originally published in Start Up
Executive Summary
To date, 2006 has seen a marked uptick in large financings by late-stage device start-ups. Average amounts raised in Series C and later deals has climbed steadily to over $22 million from just under $15 million in 2003, and an unprecedented ten device firms have raised $30 million or more in single deals so far this year.
You may also be interested in...
The Lure of Late-Stage Device Investing
In 2006, the number of late-stage private equity deals in the medical device sector is up significantly from 2005. At the IN3 East medtech conference in October, a lively panel of venture capital investors from Galen Partners, 3i, Matignon Technologies and OrbiMed Advisors discussed why this is so, and the risks, benefits and models for late-stage investing.
Late-Stage Dealmaking Takes Off
Some VCs insist that only 25%-30% of device investments find a successful exit -- significantly better than the 10% of biotech deals, but still far from a sure thing. As a result, over the past year or so, there has been a marked increase in interest in late-stage dealmaking -- investments made at Series C or later or via alternative vehicles such as PIPE deals and SPACs.
The Lure of Late-Stage Device Investing
In 2006, the number of late-stage private equity deals in the medical device sector is up significantly from 2005. At the IN3 East medtech conference in October, a lively panel of venture capital investors from Galen Partners, 3i, Matignon Technologies and OrbiMed Advisors discussed why this is so, and the risks, benefits and models for late-stage investing.